Innovation with Integrity
investors

Bruker Investor Relations

Bruker Reports First Quarter 2017 Financial Results

05/03/2017

BILLERICA, Mass., May 3, 2017 /PRNewswire/ -- Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2017.

Bruker's revenues for the first quarter of 2017 were $384.9 million, an increase of 2.5% compared to the first quarter of 2016. Excluding a 5.3% positive effect from acquisitions and a 2.0% negative effect from changes in foreign currency rates, Bruker reported a year-over-year organic revenue decline of 0.8% in the first quarter of 2017. 

First quarter 2017 GAAP earnings per diluted share (EPS) were $0.13, compared to $0.14 in the first quarter of 2016.  First quarter 2017 non-GAAP EPS were $0.19, compared to $0.21 in the first quarter of 2016. A reconciliation of non-GAAP to GAAP financial measures is provided in the tables accompanying this press release.

Frank Laukien, President and CEO of Bruker, commented: "Despite the comparison with a good first quarter of 2016, we were pleased with our first quarter of 2017, as revenue and non-GAAP operating income exceeded our expectations. While academic market conditions remain a concern, we are encouraged by another quarter of positive year-over-year order growth in Europe, continued strength in China, further stabilization in our microbiology orders, and encouraging demand trends in certain areas of our industrial, applied and semiconductor metrology markets.  We expect to return to organic revenue growth in 2017, and are on track to achieve our financial objectives."    

Fiscal Year 2017 Financial Outlook

For FY 2017, Bruker is maintaining its organic revenue growth, non-GAAP operating margin expansion and non-GAAP EPS outlook. Bruker is adjusting its reported revenue growth outlook to reflect recent changes in foreign currency translation rates. The Company now expects reported revenue growth of 2% to 3.5%, which continues to include organic revenue growth of 1% to 2%, and growth from acquisitions of 3.5% to 4%.  Changes in foreign currency rates are now expected to have a negative impact on reported revenues of approximately 2.5%.  

Bruker's outlook for non-GAAP operating margin expansion and non-GAAP EPS remains unchanged. Including the effects of our 2016 and early 2017 acquisitions, the Company continues to project an increase in FY 2017 non-GAAP operating margin of 40 bps to 70 bps year-over-year. This includes an approximate 40 bps headwind in FY 2017 from recent acquisitions. For FY 2017, Bruker continues to expect non-GAAP EPS of $1.05 to $1.09.

For the Company's outlook for FY 2017 non-GAAP operating margin and non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see "Use of Non-GAAP Financial Measures" below for a description of items excluded from our expected non-GAAP operating margin and non-GAAP EPS.

Quarterly Earnings Call

Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today at 4:45 p.m. Eastern Daylight Time.  To listen to the webcast, investors can go to http://ir.bruker.com and click on the "Events & Presentations" hyperlink.  A slide presentation that will be referenced during the webcast will be posted to the Company's website shortly before the webcast begins.  Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (US toll free) or +1-412-317-6702 (international), and referencing "Bruker's First Quarter 2017 Earnings Conference Call".  A telephone replay of the conference call will be available by dialing 1-877-344-7529 (US toll free) or +1-412-317-0088 (international) and entering conference number: 10105655. The replay will be available beginning one hour after the end of the conference through June 3, 2017.

About Bruker Corporation

For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.  Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. 

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, and in microscopy, nano-analysis and industrial applications. In recent years, Bruker has also become a provider of high-performance systems for cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology, and for molecular pathology research.  For more information, please visit: www.bruker.com.

Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures in this press release and in the earnings webcast: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating margin; non-GAAP profit before tax; non-GAAP tax rate; non-GAAP net income and non-GAAP earnings per share.  These non-GAAP measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired intangible assets and other costs that are infrequent or non-recurring in nature.

We also refer to organic revenue growth and free cash flow in this press release and in the earnings webcast, which are also non-GAAP financial measures. We define the term organic revenue as GAAP revenue excluding the effect of foreign currency changes and the effect of acquisitions and divestitures, and believe it is a useful measure to evaluate our continuing business.  We define free cash flow as net cash provided by operating activities less additions to property, plant, and equipment.  We believe free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders. 

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.  We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. 

We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business as it adjusts for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results.  We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions.  We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. 

Additional information relating to these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures is provided in the tables accompanying this press release following our GAAP financial statements. 

With respect to the Company's outlook for 2017 non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments.  These reconciling items are uncertain, depend on various factors outside our management's control and could significantly impact, either individually or in the aggregate, our future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.

Forward Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties which could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates, our ability to successfully implement our restructuring initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners, key suppliers and contract manufacturers, capital spending and government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2016 and subsequently filed Quarterly Reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

-tables follow-

 

Contacts:  
Miroslava Minkova  
Head of Investor Relations
Bruker Corporation  
T: +1 (978) 663 – 3660, ext. 1479  
E: Miroslava.Minkova@Bruker.com

 

 

Bruker Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)





(in millions)

March 31,


December 31,


2017


2016





ASSETS








Current assets:





Cash and cash equivalents

$                277.5


$                342.4


Short-term investments

187.0


157.9


Accounts receivable, net

225.4


243.9


Inventories

476.4


440.4


Other current assets

97.8


91.3



Total current assets

1,264.1


1,275.9





Property, plant and equipment, net

241.0


239.1

Intangibles, net and other long-term assets

334.8


293.4







Total assets

$             1,839.9


$             1,808.4





LIABILITIES AND SHAREHOLDERS' EQUITY








Current liabilities:





Current portion of long-term debt

$                    0.1


$                  20.1


Accounts payable

94.7


86.1


Customer advances

148.9


149.0


Other current liabilities

271.2


269.5



Total current liabilities

514.9


524.7





Long-term debt

384.7


391.6

Other long-term liabilities

208.7


199.0





Total shareholders' equity

731.6


693.1







Total liabilities and shareholders' equity

$             1,839.9


$             1,808.4

 

 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)






Three Months Ended

(in millions, except per share amounts)

March 31, 


2017


2016





Revenues

$                384.9


$                375.4

Cost of revenues

208.5


208.6





Gross profit

176.4


166.8





Operating expenses:




Selling, general and administrative

98.1


92.7

Research and development

37.6


36.1

Other charges, net

3.1


4.0

Total operating expenses

138.8


132.8





Operating income

37.6


34.0





Interest and other expense, net

(6.0)


(5.6)





Income before income taxes and noncontrolling





interest in consolidated subsidiaries

31.6


28.4

Income tax provision

9.9


4.8





Consolidated net income

21.7


23.6

Net income attributable to noncontrolling





interests in consolidated subsidiaries

0.1


-

Net income attributable to Bruker Corporation

$                  21.6


$                  23.6





Net income per common share attributable to





Bruker Corporation shareholders:





Basic

$                  0.14


$                  0.14


Diluted

$                  0.13


$                  0.14





Weighted average common shares outstanding:





Basic

159.7


163.3


Diluted

160.5


164.3

 

 

Bruker Corporation

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)



Three Months Ended 

(in millions)

 March 31, 


2017


2016

 Cash flows from operating activities:  




 Consolidated net income 

$                  21.7


$                  23.6

 Adjustments to reconcile consolidated net income to cash flows 





 from operating activities: 





 Depreciation and amortization 

15.1


13.2


 Write-down of demonstration inventories to net realizable value 

2.8


4.8


 Stock-based compensation expense 

2.6


2.2


 Deferred income taxes 

0.4


(2.7)


 Impairment and other non-cash expenses, net 

1.3


1.7

 Changes in operating assets and liabilities, net of acquisitions and divestitures: 





 Accounts receivable 

25.6


7.2


 Inventories 

(31.1)


(28.8)


 Accounts payable and accrued expenses 

(2.7)


(9.0)


 Income taxes payable, net 

(6.4)


(13.7)


 Deferred revenue 

0.9


9.2


 Customer advances 

(3.1)


(18.4)


 Other changes in operating assets and liabilities, net 

5.5


(3.3)

 Net cash provided by (used in) operating activities 

32.6


(14.0)





 Cash flows from investing activities:  





 Purchases of short-term investments 

(85.3)


(21.7)


 Maturities of short-term investments 

58.7


21.7


 Cash paid for acquisitions, net of cash acquired 

(39.8)


-


 Purchases of property, plant and equipment 

(11.5)


(8.0)


 Proceeds from sales of property, plant and equipment 

6.6


0.6

 Net cash used in investing activities 

(71.3)


(7.4)





 Cash flows from financing activities:  





 Proceeds from revolving lines of credit 

33.0


36.0


 Repayment of revolving lines of credit 

(40.0)


-


 Repayment of note purchase agreement 

(20.0)


-


 (Repayment) Proceeds of other debt, net 

(0.1)


0.4


 Proceeds from issuance of common stock, net 

1.2


7.5


 Repurchase of common stock 

-


(78.9)


 Payment of dividends 

(6.4)


(6.5)

 Net cash used in financing activities 

(32.3)


(41.5)

 Effect of exchange rate changes on cash, cash equivalents and restricted cash 

5.8


6.0

 Net change in cash, cash equivalents and restricted cash 

(65.2)


(56.9)

 Cash, cash equivalents and restricted cash at beginning of period 

345.9


271.2

 Cash, cash equivalents and restricted cash at end of period 

$                280.7


$                214.3

 

 

Bruker Corporation




RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)





(in millions, except per share amounts)

 Three Months Ended March 31, 


2017


2016

Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit
Before Tax, Non-GAAP Net Income, and Non-GAAP EPS

 




GAAP Operating Income

$                  37.6


$                     34.0

   Non-GAAP Adjustments:




Restructuring Costs

0.1


3.8

Acquisition-Related Costs

2.8


1.9

Purchased Intangible Amortization

6.9


5.4

Other Costs

1.8


2.2

   Total Non-GAAP Adjustments:

$                  11.6


$                     13.3





Non-GAAP Operating Income

$                  49.2


$                     47.3

   Non-GAAP Operating Margin

12.8%


12.6%





Non-GAAP Interest & Other Expense, net

(6.0)


(5.6)

Non-GAAP Profit Before Tax

43.2


41.7





Non-GAAP Income Tax Provision

(13.2)


(7.4)

   Non-GAAP Tax Rate

30.6%


17.7%





Minority Interest

(0.1)


-





Non-GAAP Net Income Attributable to Bruker

29.9


34.3





Weighted Average Shares Outstanding (Diluted)

160.5


164.3





Non-GAAP Earnings Per Share

$                  0.19


$                     0.21









Reconciliation of GAAP and Non-GAAP Gross Profit




GAAP Gross Profit

$                176.4


$                   166.8

   Non-GAAP Adjustments:




Restructuring Costs

(1.4)


2.0

Acquisition-Related Costs

2.5


2.0

Purchased Intangible Amortization

5.4


4.6

Other Costs

0.5


-

   Total Non-GAAP Adjustments:

7.0


8.6

Non-GAAP Gross Profit

$                183.4


$                   175.4

   Non-GAAP Gross Margin

47.6%


46.7%





Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow




GAAP Operating Cash Flow

$                  32.6


$                   (14.0)

   Non-GAAP Adjustments:




Purchases of property, plant and equipment

(11.5)


(8.0)

Non-GAAP Free Cash Flow

$                  21.1


$                   (22.0)





Reconciliation of GAAP Revenue and Non-GAAP Revenue




GAAP Revenue as of Prior Comparable Period

$                375.4


$                   353.5

   Non-GAAP Adjustments:




Acquisitions and divestitures

19.7


5.1

Currency

(7.3)


(3.0)

Organic

(2.9)


19.8

   Total Non-GAAP Adjustments:

9.5


21.9

Non-GAAP Revenue

$                384.9


$                   375.4

   Organic Revenue Growth

-0.8%


5.6%





Days Inventory Outstanding is calculated as follows: GAAP Average Inventory balance divided by (GAAP Revenue
less Non-GAAP Gross Profit (defined above)) 


Days Payable Outstanding is calculated as follows:  GAAP Average Accounts Payable balance divided by (GAAP
Revenue less Non-GAAP Gross Profit (defined above) plus the Change in GAAP Inventory balance)





Days Sales Outstanding is calculated as follows:  GAAP Average Accounts Receivable balance divided by GAAP Revenue

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bruker-reports-first-quarter-2017-financial-results-300450920.html

SOURCE Bruker Corporation

BRKR (Common Stock)

Stock Quote: NASD

Price $35.22

Change +0.07 (+0.2%)

11/22/17 04:00 PM Pricing delayed 20 minutes

Investor Contact

Miroslava Minkova
Head of Investor Relations
Bruker Corporation
P: +1 978 663 3660 x1479
E: investor.relations@bruker.com

Search Investor Relations

Follow Us LinkedIn Twitter Facebook